JAMA Network
About The Study: In this umbrella review of meta-analyses, evidence for most noncardiometabolic outcomes associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was of lower certainty. Potential safety signals were observed for gastrointestinal adverse events, while suggested protective associations with respiratory diseases and serious infections require further confirmation.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
